Precision Medicine Asia and National Cancer Center Hospital East Announce the Initiation of the LC-SCRUM-AP Genomic Screening Platform for the Asia-Pacific Region
TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.
- TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.
- LC-SCRUM-AP is a genomic screening platform for patients with advanced or recurrent non-small cell lung cancer.
- The aim is to further develop precision medicine in Asia by establishing a genomic screening infrastructure for the Asia-Pacific region.
- The integration of the LC-SCRUM-Asia and LC-SCRUM-AP databases will create an international, large-scale lung cancer clinicopathological database and contribute to the development of precision medicine in Asia.